Factors predicting recurrence after left‑sided pancreatectomy for pancreatic ductal adenocarcinoma

World Journal of Surgical Oncology

Research

Tao Xia¹  Weiwei Jin¹  Yuanyu Wang¹  Chao Lu¹  Yucheng Zhou¹  Qicong Zhu¹  Xizhou Zhang¹  Yunyun Xu¹  Peng Xu²  Yiping Mou³  Shihao Song⁴ 

[1] Department of General Surgery, Cancer Center, Division of Gastrointestinal and Pancreatic Surgery, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, China;Department of General Surgery, Cancer Center, Division of Gastrointestinal and Pancreatic Surgery, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, China;Department of Surgery, Qingdao University, Qingdao, China;Department of General Surgery, Cancer Center, Division of Gastrointestinal and Pancreatic Surgery, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, China;Department of Surgery, Qingdao University, Qingdao, China;Department of Surgery, Wenzhou Medical University, Wenzhou, China;Department of General Surgery, Cancer Center, Division of Gastrointestinal and Pancreatic Surgery, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, China;Department of Surgery, Wenzhou Medical University, Wenzhou, China;

关键词: Left‑sided pancreatectomy;    Pancreatic ductal adenocarcinoma;    Recurrence site;    Recurrence-free survival;    Predictors for recurrence;   

DOI  :  10.1186/s12957-023-03080-z

 received in 2023-04-19, accepted in 2023-06-17,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundRecurrence after resection is the main factor for poor survival. The relationship between clinicopathological factors and recurrence after curative distal pancreatectomy for PDAC has rarely been reported separately.MethodsPatients with PDAC after left‑sided pancreatectomy between May 2015 and August 2021 were retrospectively identified.ResultsOne hundred forty-one patients were included. Recurrence was observed in 97 patients (68.8%), while 44 (31.2%) patients had no recurrence. The median RFS was 8.8 months. The median OS was 24.9 months. Local recurrence was the predominant first detected recurrence site (n = 36, 37.1%), closely followed by liver recurrence (n = 35, 36.1%). Multiple recurrences occurred in 16 (16.5%) patients, peritoneal recurrence in 6 (6.2%) patients, and lung recurrence in 4 (4.1%) patients. High CA19-9 value after surgery, poor differentiation grade, and positive lymph nodes were found to be independently associated with recurrence. The patients receiving adjuvant chemotherapy had a decreased likelihood of recurrence. In the high CA19-9 value cohort, the median PFS and OS of the patients with or without chemotherapy were 8.0 VS. 5.7 months and 15.6 VS. 13.8 months, respectively. In the normal CA19-9 value cohort, there was no significant difference in PFS with or without chemotherapy (11.7 VS. 10.0 months, P = 0.147). However, OS was significantly longer in the patients with chemotherapy (26.4 VS. 13.8 months, P = 0.019).ConclusionsTumor biologic characteristics, such as T stage, tumor differentiation and positive lymph nodes, affecting CA19-9 value after surgery are associated with patterns and timing of recurrence. Adjuvant chemotherapy significantly reduced recurrence and improved survival. Chemotherapy is strongly recommended in patients with high CA199 after surgery.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

40517_2023_252_Article_IEq90.gif

40517_2023_252_Article_IEq43.gif